Research Article

Determination of Risk Factors Associated with the Failure of 12 Weeks of Direct-Acting Antiviral Therapy in Patients with Hepatitis C: A Prospective Study

Table 4

Regression coefficients and odds ratios (and 95% CIs) for risk factors associated with treatment failure after 12 weeks of DAA therapy in HCV patients ().

Independent variableSlopeSEOR (95% CI)

Intercept-8.802.840.0020.01 (0.01, 0.03)
Cirrhosis2.280.670.0019.72 (2.85, 39.28)
Genotype 20.960.850.2622.6 (0.49, 14.29)
Genotype 3-0.560.960.5590.58 (0.09, 3.81)
Genotype 6-1.170.820.0530.32 (0.06, 0.87)
Baseline AST0.030.010.0031.03 (1.02, 1.05)
Baseline ALP0.020.010.0371.02 (1.01, 1.03)
Baseline hemoglobin-0.050.020.0030.96 (0.93, 0.99)
FIB-40.610.180.0011.83 (1.36, 2.67)
Baseline viral load (log10 IU/ml)0.880.260.0012.4 (1.52, 4.17)
RVR3.951.250.00251.54 (6.39, 139.82)

RVR, rapid virological response; AST: aspartate aminotransferase; ALT: alanine transaminase; FIB-4: fibrosis index based on four factors.